ABSTRACT: A mutation (C77G) in exon 4 of the CD45 gene is the most common cause of CD45 abnormal splicing in European populations, which has been associated with an increased susceptibility to human immunodeficiency virus infection. We aimed to analyze the C77G frequency in the Spanish population.
517 healthy donors. CD45RA and RO expression was determined in circulating T lymphocytes by flow cytometry. CD45 exon 4 sequencing was carried out in individuals with an abnormal coexpression of CD45 isoforms.
6/517 individuals presented CD45RA persistence on memory T cells; all of them were heterozygous for C77G mutation. The resulting allelic frequency was 0,58% (95% confidence interval, 0.23-1.32).
C77G is present in the Spanish population. Further studies to elucidate its clinical significance are needed.
Medicina Clínica 07/2005; 125(1):10-1. · 1.38 Impact Factor
AIDS 08/2004; 18(11):1609-10. · 6.24 Impact Factor
ABSTRACT: Immune-based therapies, such as therapeutic vaccination, that might preserve, restore, enhance and induce new HIV-specific immunologic responses are currently being explored. HIV-specific immunotherapy with Remune (The Immune Response Corp.) offers the opportunity to boost immune responses against HIV-1. The clinical trial program in a wide range of subjects has established the efficacy of Remune in stimulating an appropriate immune response in HIV-positive individuals. Furthermore, a recent unblinded study conducted in Europe has documented a significant effect of Remune on viral load. Evidence regarding clinical end points is more difficult to collect. The same studies have revealed no serious safety issues in a total of more than 2000 Remune-treated patients. It is therefore reasonable to suggest that the risk-benefit ratio of Remune could be positive.
Expert Review of Vaccines 01/2004; 2(6):739-52. · 4.25 Impact Factor